Connect with us

Clinical trials

Clinical trials rules give hope to millions of patients

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

3-clinical-trials-europeOn 2 April, the European Parliament voted for a wide-ranging package of transparency measures for clinical trial data, measures that give hope to patients suffering from rare diseases.

Glenis Willmott MEP, Labour's leader in Europe and rapporteur for the clinical trials regulation, said: "I am delighted the overwhelming majority of MEPs backed the deal I reached on the clinical trials regulation. It will make trials more transparent, give hope to patients needing new and better treatments, and boost the number of skilled research jobs here in Europe.

"The new law offers hope to the millions of people in Europe suffering from rare diseases by making cross-border trials much easier to conduct.

"There are simply not enough patients in one country alone to develop new or improved treatments for rare diseases, and by working at European level we can reduce the huge cost and burden of conducting trials across borders.

"Currently around half of all clinical trials are not published, which is unacceptable.  This legislation will change that by ensuring all trials report a summary of results to a publicly accessible database, as well as the full clinical study reports once a medicine has applied for authorization."

The new regulations will also protect and create research jobs across Europe.

Willmott added: "Over the past few years Europe has been losing jobs in research as clinical trials move elsewhere in the world. By streamlining the rules, whilst keeping patient safety at heart, we can be more competitive, create new jobs and ensure Europe remains a world leader in medical research."

Advertisement

Share this article:

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter.

Trending